In patients with TC1/2/3 or IC1/2/3 PD-L1 expression inadvanced NSCLC, atezolizumab improved OS with a median OS of 15.7 months (95% CI12.6–18.0) versus 10.3 months (8.8–12.0) with docetaxel [HR 0.74(95% CI 0.58–0.93); p = 0.0102]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.